News
1 minute read

MBHB Partner Kevin Noonan Quoted In BioPharma-Reporter Article Entitled, "Six Year Wait For Humira Biosimilar A Win-Win For Amgen And AbbVie, Says Lawyer”

Kevin E. Noonan, Ph.D.October 3, 2017

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in an October 3, 2017 edition of the BioPharma-Reporter in an article entitled, “Six year wait for Humira biosimilar a win-win for Amgen and AbbVie, aays lawyer.” Amjevita (adalimumab-atto) became the first biosimilar version of AbbVie’s best-selling monoclonal antibody Humira to be approved in the US last September. European approval came in January under the name Amgevita. view the article